Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) saw unusually-high trading volume on Wednesday . Approximately 971,999 shares traded hands during mid-day trading, an increase of 394% from the previous session’s volume of 196,748 shares.The stock last traded at $1.50 and had previously closed at $1.36.

CATB has been the topic of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and set a $4.00 price objective on shares of Catabasis Pharmaceuticals in a research note on Wednesday, June 21st. Oppenheimer Holdings, Inc. lowered their price objective on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research note on Tuesday, August 15th. HC Wainwright lifted their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research cut Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Catabasis Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $4.50.

The stock’s 50 day moving average is $1.27 and its 200-day moving average is $1.35. The company’s market capitalization is $32.60 million.

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.08. On average, equities research analysts expect that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu KCG Holdings LLC acquired a new stake in Catabasis Pharmaceuticals during the 2nd quarter valued at $271,000. Oppenheimer & Co. Inc. grew its holdings in Catabasis Pharmaceuticals by 33.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Catabasis Pharmaceuticals during the 1st quarter valued at $106,000. 32.90% of the stock is owned by institutional investors and hedge funds.

WARNING: “Catabasis Pharmaceuticals, Inc. (CATB) Sees Strong Trading Volume” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.